The CCR4/CCL17 axis drives intestinal acute Graft versus Host disease after allogeneic bone marrow transplantation
Authors:
- Sebastian SchlaweckSSSebastian Schlaweck
- Oliver SchanzOSOliver Schanz
- Selina K. JorchSJSelina K. Jorch
- Glen KristiansenGKGlen Kristiansen
- Marieta TomaMTMarieta Toma
- Chrystel FloresCFChrystel Flores
- Janine Becker-GototJBJanine Becker-Gotot
- Christian KurtsCKChristian Kurts
- Peter BrossartPBPeter Brossart
- Annkristin HeineAHAnnkristin Heine
Preprint
Abstract
Acute-Graft- versus -Host disease (aGvHD) is a life-threatening complication after allogeneic stem-cell-transplantation. It is mediated by alloreactive T cells whose trafficking to aGvHD target organs is orchestrated by chemokines. We here asked whether CCL17 and its corresponding receptor CCR4 are involved in aGvHD development and severity. We applied an experimental mouse model of aGvHD in CCR4/CCL17 knockout mice and analyzed gut biopsies of GvHD patients. We show that the absence of CCR4 in transplanted T cells induced significantly less severe aGvHD. This was accompanied by reduced expression of Gata3. Mechanistically, only CD4 + , but not CD8 + CCR4 -/- T cells protected from aGvHD. We next identified dendritic cells in the small intestine to produce CCL17, which selectively recruited CD4 + T cells. IL-4 production by intestinal CD4 + T cells promoted proliferation of CD8 + T cells. In line, we detected an upregulation of CCL17 and Gata3 in human aGvHD samples. Our results indicate that local CCL17 production in aGvHD target organs recruits T cells, reinforcing local tissue damage and immune cell recruitment. We identified the JAK1/2-inhibitor ruxolitinib to dampen CCL17-expression, thereby reducing GvHD severity. We here dissect a to date unknown role of the CCL17-CCR4 axis in aGvHD, which might help to develop novel therapeutic strategies.Keywords
This publication has 48 references indexed in Scilit:
- Single-Cell Analysis of Crohn’s Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF TherapyCell, 2019
- Statins can suppress DC‐mediated Th2 responses through the repression of OX40‐ligand and CCL17 expressionEuropean Journal of Immunology, 2019
- Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical TrialTransplantation and Cellular Therapy, 2019
- Chemokine CCL17 is expressed by dendritic cells in the CNS during experimental autoimmune encephalomyelitis and promotes pathogenesis of diseaseBrain, Behavior, and Immunity, 2017
- In Vivo Myeloperoxidase Imaging and Flow Cytometry Analysis of Intestinal Myeloid Cells2016
- The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCKLeukemia, 2016
- Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumabInternational Journal of Hematology, 2015
- The Chemokine Superfamily RevisitedImmunity, 2012
- IL‐33 is a chemoattractant for human Th2 cellsEuropean Journal of Immunology, 2007
- Cross-presentation: a general mechanism for CTL immunity and toleranceImmunology Today, 1998